← Russell 3000 cross-section

ZVRA ZEVRA THERAPEUTICS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$698m
Revenue TTM
$136m
Net income TTM
$58m
Free cash flow
$33m
Composite score
88.5
Sector rank
#2230

Valuation

P / E
12.0
EV / EBITDA
5.7
EV / sales
3.5
FCF yield
4.67%
Earnings yield vs 10-yr
3.62pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
42.8%
EBITDA margin
61.6%
ROE
26.8%
ROIC
Revenue growth
119.4%

Insider activity, last 90 days

Net open-market
$-1.05m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

(“Aquestive”) (the “Aquestive Termination Agreement”), Aquestive has the right to receive an amount equal to 10 % of any value generated by AZSTARYS and any product candidates containing SDX, including the sales proceeds under the Commave Settlement Agreement. Accordingly, in connection with the Commave Settlement Agreement, Aquestive received 10 % of the Company's sales proceeds. The Company will pay Citizens JMP a commission equal to 3.0 % in the aggregate of the gross sales proceeds of any common stock sold through Citizens JMP under the 2024 ATM Agreement. …ZEVRA THERAPEUTICS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →